

Nanophase Separation of Poly(*N*-alkyl acrylamides): The Dependence of the Formation of Lamellar Structures on Their Alkyl Side Chains

Kazuki Ebata,[†] Yuki Hashimoto,[†] Shunsuke Yamamoto,[‡] Masaya Mitsuishi,[‡] Shusaku Nagano,[§] and Jun Matsui^{†}*

[†]Graduate School of Science and Engineering, Yamagata University, 1-4-12 Kojirakawa-machi,
Yamagata 990-8560, Japan

[‡]Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, 2-1-1
Katahira, Aoba-ku, Sendai 980-8577, Japan

[§]Nagoya University Venture Business Laboratory, Nagoya University, Furo-cho, Chikusa, Nagoya
464-8603, Japan

[†]Faculty of Science, Yamagata University, 1-4-12 Kojirakawa-machi, Yamagata 990-8560, Japan

*Author to whom correspondence should be addressed; e-mail: jun_m@sci.kj.yamagata-u.ac.jp

Synthesis of *N*-alkyl acrylamides

N-alkyl amine (TCI, Japan) was dissolved in chloroform to the concentration of 0.1 M. To this solution, triethylamine (1.2 equivalent to *N*-alkyl amine, TCI, Japan) was added. The solution was cooled at 0 °C and acryloyl chloride (1.2 equivalent to *N*-alkyl amine) was added dropwise. After addition of acryloyl chloride, the solution was heated to room temperature and reaction was carried out for 3h. Then the reaction solution was washed with 5 wt% HCl, saturated Na₂CO₃, and saturated NaCl. The organic solution was collected and dried with Na₂SO₄. The crude products were purified by vacuum distillation for *n* = 4 (0.3 Torr, 55 °C,) and *n* = 5 (0.3 Torr, 80 °C) or recrystallization from chloroform-hexane mixed solvent for *n* ≥ 6. The purified compounds were characterized with ¹H NMR spectra.

butylacrylamide (*n*=4)

¹H NMR (500 MHz, CDCl₃) δ (δ in ppm): 6.27 (dd, 1H, H₂C=CH-), 6.11 (dd, 1H, HHC=CH-), 5.85 (s, 1H, -NH-CH₂-CH₂-), 5.62 (dd, 1H, HHC=CH-), 3.33 (q, 2H, -NH-CH₂-CH₂-), 1.50-1.56 (m, 2H, -NH-CH₂-CH₂-CH₂-CH₃), 1.37 (m, 2H, -NH-CH₂-CH₂-CH₂-CH₃), 0.93 (t, 3H, -NH-CH₂-CH₂-CH₂-CH₃)

pentylacrylamide (*n*=5)

¹H NMR (500 MHz, CDCl₃) δ: 6.27 (dd, 1H, H₂C=CH-), 6.11 (dd, 1H, HHC=CH-), 5.86 (s, 1H, -NH-CH₂-CH₂-), 5.62 (dd, 1H, HHC=CH-), 3.32 (q, 2H, -NH-CH₂-CH₂-), 1.51-1.57 (m, 2H, -NH-CH₂-CH₂-(CH₂)₂-CH₃), 1.30-1.36 (m, 4H, -NH-CH₂-CH₂-(CH₂)₂-CH₃), 0.90 (t, 3H, -NH-CH₂-CH₂-(CH₂)₂-CH₃)

hexylacrylamide (*n*=6)

¹H NMR (500 MHz, CDCl₃) δ: 6.26 (dd, 1H, H₂C=CH-), 6.08 (dd, 1H, HHC=CH-), 5.63 (dd, 1H, HHC=CH-), 5.55 (s, 1H, -NH-CH₂-CH₂-), 3.27-3.35 (m, 2H, -NH-CH₂-CH₂-), 1.51-1.56 (m, 2H, -NH-CH₂-CH₂-(CH₂)₃-CH₃), 1.25-1.37 (m, 6H, -NH-CH₂-CH₂-(CH₂)₃-CH₃), 0.89 (t, 3H, -NH-CH₂-CH₂-(CH₂)₃-CH₃)

heptylacrylamide (*n*=7)

¹H NMR (500 MHz, CDCl₃) δ: 6.27 (dd, 1H, H₂C=CH-), 6.07 (dd, 1H, HHC=CH-), 5.63 (dd, 1H, HHC=CH-), 5.51 (s, 1H, -NH-CH₂-CH₂-), 3.33 (q, 2H, -NH-CH₂-CH₂-), 1.53 (m, 2H, -NH-CH₂-CH₂-(CH₂)₄-CH₃), 1.28-1.33 (m, 8H, -NH-CH₂-CH₂-(CH₂)₄-CH₃), 0.88 (t, 3H, -NH-CH₂-CH₂-(CH₂)₄-CH₃)

octylacrylamide (*n*=8)

1H NMR (500 MHz, CDCl₃) δ:6.25 (dd, 1H, H₂C=CH-), 6.05 (dd, 1H, HHC=CH-), 5.61 (dd, 1H, HHC=CH-), 5.47 (s, 1H, -NH-CH₂-CH₂-), 3.26-3.33 (m, 2H, -NH-CH₂-CH₂-), 1.49-1.59 (m, 2H, -NH-CH₂-CH₂-(CH₂)₅-CH₃), 1.18-1.31 (m, 10H, -NH-CH₂-CH₂-(CH₂)₅-CH₃), 0.86 (t, 3H, -NH-CH₂-CH₂-(CH₂)₅-CH₃)

nonylacrylamide (*n*=9)

1H NMR (500 MHz, CDCl₃) δ:6.27 (dd, 1H, H₂C=CH-), 6.07 (dd, 1H, HHC=CH-), 5.63 (dd, 1H, HHC=CH-), 5.49 (s, 1H, -NH-CH₂-CH₂-), 3.33 (q, 2H, -NH-CH₂-CH₂-), 1.56 (m, 2H, -NH-CH₂-CH₂-(CH₂)₆-CH₃), 1.26-1.31 (m, 12H, -NH-CH₂-CH₂-(CH₂)₆-CH₃), 0.88 (t, 3H, -NH-CH₂-CH₂-(CH₂)₆-CH₃)

decylacrylamide (*n*=10)

1H NMR (500 MHz, CDCl₃) δ:6.27 (dd, 1H, H₂C=CH-), 6.06 (dd, 1H, HHC=CH-), 5.62 (dd, 1H, HHC=CH-), 5.49 (s, 1H, -NH-CH₂-CH₂-), 3.32 (q, 2H, -NH-CH₂-CH₂-), 1.51 (m, 2H, -NH-CH₂-CH₂-(CH₂)₇-CH₃), 1.25-1.30 (m, 14H, -NH-CH₂-CH₂-(CH₂)₇-CH₃), 0.87 (t, 3H, -NH-CH₂-CH₂-(CH₂)₇-CH₃)

undecylacrylamide (*n*=11)

1H NMR (500 MHz, CDCl₃) δ:6.27 (dd, 1H, H₂C=CH-), 6.07 (dd, 1H, HHC=CH-), 5.63 (dd, 1H, HHC=CH-), 5.49 (s, 1H, -NH-CH₂-CH₂-), 3.33 (q, 2H, -NH-CH₂-CH₂-), 1.55 (m, 2H, -NH-CH₂-CH₂-(CH₂)₈-CH₃), 1.21-1.31 (m, 16H, -NH-CH₂-CH₂-(CH₂)₈-CH₃), 0.88 (t, 3H, -NH-CH₂-CH₂-(CH₂)₈-CH₃)

dodecylacrylamide (*n*=12)

1H NMR (500 MHz, CDCl₃) δ:6.27 (dd, 1H, H₂C=CH-), 6.08 (dd, 1H, HHC=CH-), 5.63 (dd, 1H, HHC=CH-), 5.53 (s, 1H, -NH-CH₂-CH₂-), 3.31-3.35 (m, 2H, -NH-CH₂-CH₂-), 1.50-1.56 (m, 2H, -NH-CH₂-CH₂-(CH₂)₉-CH₃), 1.26-1.31 (m, 18H, -NH-CH₂-CH₂-(CH₂)₉-CH₃), 0.88 (t, 3H, -NH-CH₂-CH₂-(CH₂)₉-CH₃)

tridecylacrylamide (*n*=13)

1H NMR (500 MHz, CDCl₃) δ:6.27 (dd, 1H, H₂C=CH-), 6.07 (dd, 1H, HHC=CH-), 5.63 (dd, 1H, HHC=CH-), 5.50 (s, 1H, -NH-CH₂-CH₂-), 3.33 (q, 2H, -NH-CH₂-CH₂-), 1.50-1.57 (m, 2H, -NH-CH₂-CH₂-(CH₂)₁₀-CH₃), 1.21-1.31 (m, 20H, -NH-CH₂-CH₂-(CH₂)₁₀-CH₃), 0.88 (t, 3H, -NH-CH₂-CH₂-(CH₂)₁₀-CH₃)

tetradecylacrylamide (*n*=14)

1H NMR (500 MHz, CDCl₃) δ:6.27 (dd, 1H, H₂C=CH-), 6.07 (dd, 1H, HHC=CH-), 5.63 (dd, 1H, HHC=CH-), 5.49 (s, 1H, -NH-CH₂-CH₂-), 3.33 (q, 2H, -NH-CH₂-CH₂-), 1.50-1.56 (m, 2H, -NH-CH₂-CH₂-(CH₂)₁₁-CH₃), 1.25-1.31 (m, 22H, -NH-CH₂-CH₂-(CH₂)₁₁-CH₃), 0.88 (t, 3H, -NH-CH₂-CH₂-(CH₂)₁₁-CH₃)

pentadecylacrylamide (*n*=15)

1H NMR (500 MHz, CDCl₃) δ:6.27 (dd, 1H, H₂C=CH-), 6.07 (dd, 1H, HHC=CH-), 5.63 (dd, 1H, HHC=CH-), 5.49 (s, 1H, -NH-CH₂-CH₂-), 3.33 (q, 2H, -NH-CH₂-CH₂-), 1.50-1.56 (m, 2H, -NH-CH₂-CH₂-(CH₂)₁₂-CH₃), 1.25-1.31 (m, 24H, -NH-CH₂-CH₂-(CH₂)₁₂-CH₃), 0.88 (t, 3H, -NH-CH₂-CH₂-(CH₂)₁₂-CH₃)

hexadecylacrylamide (*n*=16)

1H NMR (500 MHz, CDCl₃) δ:6.27 (dd, 1H, H₂C=CH-), 6.07 (dd, 1H, HHC=CH-), 5.63 (dd, 1H, HHC=CH-), 5.49 (s, 1H, -NH-CH₂-CH₂-), 3.33 (q, 2H, -NH-CH₂-CH₂-), 1.52-1.56 (m, 2H, -NH-CH₂-CH₂-(CH₂)₁₃-CH₃), 1.25-1.31 (m, 26H, -NH-CH₂-CH₂-(CH₂)₁₃-CH₃), 0.88 (t, 3H, -NH-CH₂-CH₂-(CH₂)₁₃-CH₃)

heptadecylacrylamide (*n*=17)

1H NMR (500 MHz, CDCl₃) δ:6.27 (dd, 1H, H₂C=CH-), 6.07 (dd, 1H, HHC=CH-), 5.63 (dd, 1H, HHC=CH-), 5.51 (s, 1H, -NH-CH₂-CH₂-), 3.33 (q, 2H, -NH-CH₂-CH₂-), 1.53 (m, 2H, -NH-CH₂-CH₂-(CH₂)₁₄-CH₃), 1.25-1.31 (m, 28H, -NH-CH₂-CH₂-(CH₂)₁₄-CH₃), 0.88 (t, 3H, -NH-CH₂-CH₂-(CH₂)₁₄-CH₃)

octadecylacrylamide (*n*=18)

1H NMR (500 MHz, CDCl₃) δ:6.27 (dd, 1H, H₂C=CH-), 6.07 (dd, 1H, HHC=CH-), 5.63 (dd, 1H, HHC=CH-), 5.49 (s, 1H, -NH-CH₂-CH₂-), 3.33 (q, 2H, -NH-CH₂-CH₂-), 1.50-1.58 (m, 2H, -NH-CH₂-CH₂-(CH₂)₁₅-CH₃), 1.25-1.31 (m, 30H, -NH-CH₂-CH₂-(CH₂)₁₅-CH₃), 0.88 (t, 3H, -NH-CH₂-CH₂-(CH₂)₁₅-CH₃)

$CH_2-(CH_2)_{15}-CH_3$, 1.22-1.31 (m, 30H, -NH-CH₂-CH₂-(CH₂)₁₅-CH₃), 0.88 (t, 3H, -NH-CH₂-CH₂-(CH₂)₁₅-CH₃)




Figure S1. Tg for p(AlkylAms). The dotted line is a guide for the eye.




Figure S2. Dependence of alkyl nanodomain sizes with n .




Figure S3. FT-IR spectra of lamellar film of p(AlkylAms) ($n = 8-18$) at the amide region.




Figure S4 AFM images for p(AlkylMA). Left pristine and right water annealed film. White scale bar in the images indicate 200 nm




Figure S4 Continued




Figure S4 Continued




Figure S4 Continued